Establishment and detailed functional and molecular genetic characterisation of a novel sacral chordoma cell line, MUG-Chor1

International Journal of Oncology

Volumn 40, Issue 2, 2012, Pages 443-451

  Rinner, Beate ^a   Froehlich, Elke Verena ^a   Buerger, Karin ^a   Knausz, Heike ^a   Lohberger, Birgit ^a   Scheipl, Susanne ^a   Fischer, Carina ^a   Leithner, Andreas ^a   Guelly, Christian ^a   Trajanoski, Slave ^a   Szuhai, Karoly ^b   Liegl, Bernadette ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Brachyury; Cell line; Chordoma; Matrix metallo proteinases

Indexed keywords

GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; STROMELYSIN;

ADULT; ARTICLE; CASE REPORT; CELL LINE MUG CHOR1; CHORDOMA; CYTOGENETICS; FEMALE; FIBROBLAST; FLUORESCENCE IN SITU HYBRIDIZATION; GENE LOCUS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; KARYOTYPE; LOW BACK PAIN; MOLECULAR GENETICS; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL NEUROPATHY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RADIOGRAPHY; SACRAL CHORDOMA; TUMOR CELL LINE; TUMOR GROWTH; TUMOR VOLUME; WESTERN BLOTTING;

CELL LINE, TUMOR; CHORDOMA; COCCYX; FEMALE; GENE DOSAGE; GENOTYPE; HUMANS; KARYOTYPE; LOSS OF HETEROZYGOSITY; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; SACRUM; SPINAL NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84855690102     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1235     Document Type: Article

References (46)

1. Fletcher CDM, Unni KK and Mertens F (eds): Pathology and Genetics of Tumours of Soft Tissue and Bone. World Health Organization Classification of Tumours. Vol. 5. IARC Press, Lyon, 2002.
2. Chugh R, Tawbi H, Lucas DR, Biermann JS, Schuetze SM and Baker LH: Chordoma: The nonsarcoma primary bone tumor. Oncologist 12: 1344-1350, 2007. (Pubitemid 350232608)
3. Cummings BJ, Hodson DI and Bush RS: Chordoma: the results of megavoltage radiation therapy. Int J Radiat Oncol Biol Phys 9: 633-642, 1983. (Pubitemid 13106626)
4. Forsyth PA, Cascino TL, Shaw EG, Scheithauer BW, O'Fallon JR, Dozier JC and Piepgras DG: Intracranial chordomas: a clinico-pathological and prognostic study of 51 cases. J Neurosurg 78: 741-747, 1993. (Pubitemid 23121915)
5. Hallor KH, Staaf J, Jonsson G, Heidenblad M, Vult von Steyern F, Bauer HC, Ijszenga M, Hogendoorn PC, Mandahl N, Szuhai K and Mertens F: Frequent deletion of the CDKN2A locus in chordoma: analysis of chromosomal imbalances using array comparative genomic hybridisation. Br J Cancer 98: 434-442, 2008.
6. Henderson SR, Guiliano D, Presneau N, McLean S, Frow R, Vujovic S, Anderson J, Sebire N, Whelan J, Athanasou N, Flanagan AM and Boshoff C: A molecular map of mesenchymal tumors. Genome Biol 6: R76, 2005.
7. Romeo S and Hogendoorn PC: Brachyury and chordoma: the chondroid-chordoid dilemma resolved? J Pathol 209: 143-146, 2006. (Pubitemid 43805408)
8. Vujovic S, Henderson S, Presneau N, Odell E, Jacques TS, Tirabosco R, Boshoff C, and Flanagan AM: Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas. J Pathol 209: 157-165, 2006. (Pubitemid 43805410)
9. Heikinheimo K, Persson S, Kindblom LG, Morgan PR and Virtanen I: Expression of different cytokeratin subclasses in human chordoma. J Pathol 164: 145-150, 1991.
10. Coindre JM, Rivel J, Trojani M, De Mascarel I and De Mascarel A: Immunohistological study in chordomas. J Pathol 150: 61-63, 1986. (Pubitemid 16008197)
11. Salisbury JR: Demonstration of cytokeratins and an epithelial membrane antigen in chondroid chordoma. J Pathol 153: 37-40, 1987.
12. Showell C, Binder O and Conlon FL: T-box genes in early embryogenesis. Dev Dyn 229: 201-218, 2004. (Pubitemid 38036834)
13. Tirabosco R, Mangham DC, Rosenberg AE, Vujovic S, Bousdras K, Pizzolitto S, De Maglio G, den Bakker MA, Di Francesco L, Kalil RK, Athanasou NA, O'Donnell P, et al: Brachyury expression in extra-axial skeletal and soft tissue chordomas: a marker that distinguishes chordoma from mixed tumor/myoepithelioma/ parachordoma in soft tissue. Am J Surg Pathol 32: 572-580, 2008. (Pubitemid 351459578)
14. Presneau N, Shalaby A, Ye H, Pillay N, Halai D, Idowu B, Tirabosco R, Whitwell D, Jacques TS, Kindblom LG, Brüderlein S, Moller P, et al: Role of the transcription factor T (brachyury) in the pathogenesis of sporadic chordoma: a genetic and functional-based study. J Pathol 223: 327-335, 2011.
15. Presneau N, Shalaby A, Idowu B, Gikas P, Cannon SR, Gout I, Diss T, Tirabosco R and Flanagan AM: Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathway. Br J Cancer 100: 1406-1414, 2009.
16. Shalaby AA, Presneau N, Idowu BD, Thompson L, Briggs TR, Tirabosco R, Diss TC and Flanagan AM: Analysis of the fibroblastic growth factor receptor-RAS/RAF/MEK/ERK-ETS2/brachyury signalling pathway in chordomas. Mod Pathol 22: 996-1005, 2009.
17. Shalaby A, Presneau N, Ye H, Halai D, Berisha F, Idowu B, Leithner A, Liegl B, Briggs TR, Bacsi K, Kindblom LG, Athanasou N, et al: The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target. J Pathol 223: 336-346, 2011.
18. Han S, Polizzano C, Nielsen GP, Hornicek FJ, Rosenberg AE and Ramesh V: Aberrant hyperactivation of akt and Mammalian target of rapamycin complex 1 signaling in sporadic chordomas. Clin Cancer Res 15: 1940-1946, 2009.
19. Sommer J, Itani DM, Homlar KC, Keedy VL, Halpern JL, Holt GE, Schwartz HS, Coffin CM, Kelley MJ and Cates JM: Methylthioadenosine phosphorylase and activated insulin-like growth factor-1 receptor/insulin receptor: potential therapeutic targets in chordoma. J Pathol 220: 608-617, 2010.
20. Bruderlein S, Sommer JB, Meltzer PS, Li S, Osada T, Ng D, Moller P, Alcorta DA and Kelley MJ. Molecular characterization of putative chordoma cell lines. Sarcoma 2010: 630129, 2010.
21. Scheil S, Bruderlein S, Liehr T, Starke H, Herms J, Schulte M and Moller P: Genome-wide analysis of sixteen chordomas by comparative genomic hybridization and cytogenetics of the first human chordoma cell line, U-CH1. Genes Chromosomes Cancer 32: 203-211, 2001. (Pubitemid 32953974)
22. Polinger IS: Separation of cell types in embryonic heart cell cultures. Exp Cell Res 63: 78-82, 1970.
23. Freshney RI: Culture of Animal Cells: A Manual of Basic Technique. 5th edition. Wiley-Liss, Hoboken, NJ, 2005.
24. Szuhai K, IJszenga M, Tanke HJ, Taminiau AH, de Schepper A, van Duinen SG, Rosenberg C and Hogendoorn PC: Detection and molecular cytogenetic characterization of a novel ring chromosome in a histological variant of Ewing sarcoma. Cancer Genet Cytogenet 172: 12-22, 2007. (Pubitemid 44908688)
25. Szuhai K and Tanke HJ: COBRA: combined binary ratio labeling of nucleic-acid probes for multi-color fluorescence in situ hybridization karyotyping. Nat Protoc 1: 264-275, 2006.
26. Sawyer JR, Husain M and Al-Mefty O: Identification of isochromosome 1q as a recurring chromosome aberration in skull base chordomas: a new marker for aggressive tumors? Neurosurg Focus 10: E6, 2001.
27. Tallini G, Dorfman H, Brys P, Dal Cin P, De Wever I, Fletcher CD, Jonson K, Mandahl N, Mertens F, Mitelman F, Rosai J, Rydholm A, et al: Correlation between clinicopathological features and karyotype in 100 cartilaginous and chordoid tumours. A report from the Chromosomes and Morphology (CHAMP) Collaborative Study Group. J Pathol 196: 194-203, 2002. (Pubitemid 34110901)
28. Kuzniacka A, Mertens F, Strombeck B, Wiegant J and Mandahl N: Combined binary ratio labeling fluorescence in situ hybridization analysis of chordoma. Cancer Genet Cytogenet 151: 178-181, 2004. (Pubitemid 38692819)
29. Brandal P, Bjerkehagen B, Danielsen H and Heim S: Chromosome 7 abnormalities are common in chordomas. Cancer Genet Cytogenet 160: 15-21, 2005. (Pubitemid 40798131)
30. Yang XR, Beerman M, Bergen AW, Parry DM, Sheridan E, Liebsch NJ, Kelley MJ, Chanock S and Goldstein AM: Corroboration of a familial chordoma locus on chromosome 7q and evidence of genetic heterogeneity using single nucleotide polymorphisms (SNPs). Int J Cancer 116: 487-491, 2005. (Pubitemid 40993348)
31. Miozzo M, Dalpra L, Riva P, Volonta M, Macciardi F, Pericotti S, Tibiletti MG, Cerati M, Rohde K, Larizza L and Fuhrman Conti AM: A tumor suppressor locus in familial and sporadic chordoma maps to 1p36. Int J Cancer 87: 68-72, 2000. (Pubitemid 30368417)
32. Riva P, Crosti F, Orzan F, Dalpra L, Mortini P, Parafioriti A, Pollo B, Fuhrman Conti AM, Miozzo M and Larizza L: Mapping of candidate region for chordoma development to 1p36.13 by LOH analysis. Int J Cancer 107: 493-497, 2003. (Pubitemid 37266472)
33. Yang XR, Ng D, Alcorta DA, Liebsch NJ, Sheridan E, Li S, Goldstein AM, Parry DM and Kelley MJ: T (brachyury) gene duplication confers major susceptibility to familial chordoma. Nat Genet 41: 1176-1178, 2009.
34. Stahl JM, Cheung M, Sharma A, Trivedi NR, Shanmugam S and Robertson GP: Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res 63: 2881-2890, 2003. (Pubitemid 36667160)
35. Wu H, Goel V and Haluska FG: PTEN signaling pathways in melanoma. Oncogene 22: 3113-3122, 2003. (Pubitemid 36713763)
36. Lankat-Buttgereit B and Goke R: The tumour suppressor PDCD4: recent advances in the elucidation of function and regulation. Biol Cell 101: 309-317, 2009.
37. Leupold JH, Yang HS, Colburn NH, Asangani I, Post S and Allgayer H: Tumor suppressor PDCD4 inhibits invasion/intravasation and regulates urokinase receptor (u-PAR) gene expression via Sp-transcription factors. Oncogene 26: 4550-4562, 2007. (Pubitemid 47039134)
38. Fosang AJ, Last K, Knauper V, Neame PJ, Murphy G, Hardingham TE, Tschesche H and Hamilton JA: Fibroblast and neutrophil collagenases cleave at two sites in the cartilage aggrecan interglobular domain. Biochem J 295 (Pt 1): 273-276, 1993. (Pubitemid 23298337)
39. Naka T, Kuester D, Boltze C, Schulz TO, Samii A, Herold C, Ostertag H and Roessner A: Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma. Hum Pathol 39: 217-223, 2008.
40. Foukas AF, Deshmukh NS, Grimer RJ, Mangham DC, Mangos EG, Taylor S: Stage-IIB osteosarcomas around the knee. A study of MMP-9 in surviving tumour cells. J Bone Joint Surg Br 84: 706-711, 2002.
41. Uchibori M, Nishida Y, Nagasaka T, Yamada Y, Nakanishi K and Ishiguro N: Increased expression of membrane-type matrix metalloproteinase-1 is correlated with poor prognosis in patients with osteosarcoma. Int J Oncol 28: 33-42, 2006.
42. Hackel C, Czerniak B, Ayala AG, Radig K and Roessner A: Expression of plasminogen activators and plasminogen activator inhibitor 1 in dedifferentiated chondrosarcoma. Cancer 79: 53-58, 1997. (Pubitemid 26425507)
43. Hackel CG, Krueger S, Grote HJ, Oshiro Y, Hodges S, Johnston DA, Johnson ME, Roessner A, Ayala AG and Czerniak B: Overexpression of cathepsin B and urokinase plasminogen activator is associated with increased risk of recurrence and metastasis in patients with chondrosarcoma. Cancer 89: 995-1003, 2000.
44. Kawashima A, Okada Y, Nakanishi I, Ueda Y, Iwata K and Roessner A: Immunolocalization of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human chondrosarcomas. Gen Diagn Pathol 142: 129-137, 1997. (Pubitemid 27104362)
45. Naka T, Boltze C, Samii A, Samii M, Herold C, Ostertag H, Iwamoto Y, Oda Y, Tsuneyoshi M, Kuester D and Roessner A: Expression of c-MET, low-molecular-weight cytokeratin, matrix metalloproteinases-1 and -2 in spinal chordoma. Histopathology 54: 607-613, 2009.
46. Overall CM and Kleifeld O: Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 6: 227-239, 2006. (Pubitemid 43292566)